Summary
Betaxolol is a cardioselective beta-blocker, which has a bioavailability of 90% and a T1/2 of 20 h. A four group, cross-over double-blind trial was conducted to select between betaxolol 20 mg and 40 mg for long term trials. 60 patients were allocated randomly to one of the sequences placebo-20 mg, 20 mg-placebo, placebo-40 mg and 40 mg-placebo, each treatment lasting for 2 weeks. Groups were homogenous for baseline diastolic blood pressure (DBP), age and male/female ratio, and were slightly unbalanced for weight. A two-way ANOVA (3 treatments, 2 sequences) showed no treatment-sequence interaction nor sequence effect. The mean reduction in DBP was 14.2±1.8 mm Hg following 20 mg and 18.0±1.8 following 40 mg betaxolol, and 4.0±1.2 mm Hg during placebo (p<0.001). Age, weight, baseline DBP and duration of hypertension did not influence the treatment effect. The 95% confidence intervals of the reduction in DBP were 10.4–17.9 for 20 mg and 14.3–21.6 mm Hg for betaxolol 40 mg. Aiming at a mean reduction to 90 mm Hg, betaxolol 20 mg would appear to be adequate in similar patient populations.
Similar content being viewed by others
References
Giudicelle JF, Chauvin M, Thuillez C, Richer G, Bianchetti G, Gomeni R, Morselli PL (1980) Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol 10: 41–49
Warrington SJ, Turner P, Kilborn JR, Bianchetti G, Morselli PL (1980) Blood concentration and pharmacodynamic effects of betaxolol (SL 75212), a new beta-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol 10: 449–452
Balnave K, Neill JD, Russel CJ, Harron DWG, Leahey WJ, Wilson R and Shanks RG (1980) Observations on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol 11: 171–180
Nie NH, Hull CH, Jenkins JG, Steinbrenner K, Bent DH (1970) Statistical package for social sciences (1969). 2nd ed. McGraw-Hill, New York
Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, and Morledge J (1978) Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 24: 192–198
Serlin MJ, Orme ML'E, Barber NS, Sibeon RG, Laws E, Brenkenridge A (1980) Propanolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther 27: 586–592
Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8: 7–20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salonen, J.T., Palminteri, R. Comparison of two doses of betaxolol and placebo in hypertension: A randomized, double-blind cross-over trial. Eur J Clin Pharmacol 23, 491–494 (1982). https://doi.org/10.1007/BF00637494
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637494